Formula optimization and in vivo study of poly(L-glutamic acid)-g-methoxy poly(ethylene glycol)/combretastatin A4/BLZ945 nanoparticles for cancer therapy
[Display omitted] Poly(L-glutamic acid)-g-methoxy poly(ethylene glycol)/Combretastatin A4 (CA4)/BLZ945 nanoparticles (CB-NPs) have shown great potential in synergistic cancer therapy. However, it is still unclear how the nanoparticles’ formula, such as injection dose, active agent ratio, and drug lo...
Gespeichert in:
| Veröffentlicht in: | International journal of pharmaceutics 2023-04, Vol.636, p.122849-122849, Article 122849 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 122849 |
|---|---|
| container_issue | |
| container_start_page | 122849 |
| container_title | International journal of pharmaceutics |
| container_volume | 636 |
| creator | Huang, Yue Yang, Chenguang lv, Jianlin Zhang, Yu Wang, Kun Ma, Lili Liu, Zhilin Yu, Haiyang Li, Mingqiang Tang, Zhaohui |
| description | [Display omitted]
Poly(L-glutamic acid)-g-methoxy poly(ethylene glycol)/Combretastatin A4 (CA4)/BLZ945 nanoparticles (CB-NPs) have shown great potential in synergistic cancer therapy. However, it is still unclear how the nanoparticles’ formula, such as injection dose, active agent ratio, and drug loading content, affects the side effects and in vivo efficacy of CB-NPs. In this study, a series of CB-NPs with different BLZ945/CA4 (B/C) ratios and drug loading contents were synthesized and evaluated on a hepatoma (H22) tumor-bearing mice model. The injection dose and B/C ratio were found to have a significant influence on the in vivo anticancer efficacy. The CB-NPs 20 with B/C weight ratio of 0.45/1, and total drug loading content (B + C) of 20.7 wt%, showed the highest potential for clinical application. Systematic pharmacokinetics, biodistribution, and in vivo efficacy evaluation for CB-NPs 20 have been finished, which may provide significant instruction for medicine screening and clinical application. |
| doi_str_mv | 10.1016/j.ijpharm.2023.122849 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2791373018</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0378517323002697</els_id><sourcerecordid>2791373018</sourcerecordid><originalsourceid>FETCH-LOGICAL-c365t-22dac13daecd59a30ebaf1faec1f0df19d1198ab7192e541c9c816dc91c050083</originalsourceid><addsrcrecordid>eNqFkc-O0zAQxiMEYsvCI4B83D2k9dj55xPaXbELUiUucOFiufakdeXEwXYqwpvwtqRKlyunmdF8M59mfln2HugaKFSb49oeh4MK3ZpRxtfAWFOIF9kKmprnvKirl9mK8rrJS6j5VfYmxiOltGLAX2dXvBKclw1bZX8efehGp4gfku3sb5Ws74nqDbE9OdmTJzGNZiK-JYN3080237sxqc5qorQ1t_k-7zAd_K9p6c_55LBHsneT9u52o323C5hUTPPqntwVm_vtD1GUpFe9H1RIVjuMpPWBaNVrDCQdMKhhepu9apWL-O4Sr7Pvj5--PXzOt1-fvjzcbXPNqzLljBmlgRuF2pRCcYo71UI7l9BS04IwAKJRuxoEw7IALXQDldECNC0pbfh1drPsHYL_OWJMsrNRo3OqRz9GyWoBvOYUztJykergYwzYyiHYToVJApVnKvIoL1TkmYpcqMxzHy4W465D82_qGcMs-LgIcD70ZDHIqC3O3zA2oE7SePsfi7-agqPP</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2791373018</pqid></control><display><type>article</type><title>Formula optimization and in vivo study of poly(L-glutamic acid)-g-methoxy poly(ethylene glycol)/combretastatin A4/BLZ945 nanoparticles for cancer therapy</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Huang, Yue ; Yang, Chenguang ; lv, Jianlin ; Zhang, Yu ; Wang, Kun ; Ma, Lili ; Liu, Zhilin ; Yu, Haiyang ; Li, Mingqiang ; Tang, Zhaohui</creator><creatorcontrib>Huang, Yue ; Yang, Chenguang ; lv, Jianlin ; Zhang, Yu ; Wang, Kun ; Ma, Lili ; Liu, Zhilin ; Yu, Haiyang ; Li, Mingqiang ; Tang, Zhaohui</creatorcontrib><description>[Display omitted]
Poly(L-glutamic acid)-g-methoxy poly(ethylene glycol)/Combretastatin A4 (CA4)/BLZ945 nanoparticles (CB-NPs) have shown great potential in synergistic cancer therapy. However, it is still unclear how the nanoparticles’ formula, such as injection dose, active agent ratio, and drug loading content, affects the side effects and in vivo efficacy of CB-NPs. In this study, a series of CB-NPs with different BLZ945/CA4 (B/C) ratios and drug loading contents were synthesized and evaluated on a hepatoma (H22) tumor-bearing mice model. The injection dose and B/C ratio were found to have a significant influence on the in vivo anticancer efficacy. The CB-NPs 20 with B/C weight ratio of 0.45/1, and total drug loading content (B + C) of 20.7 wt%, showed the highest potential for clinical application. Systematic pharmacokinetics, biodistribution, and in vivo efficacy evaluation for CB-NPs 20 have been finished, which may provide significant instruction for medicine screening and clinical application.</description><identifier>ISSN: 0378-5173</identifier><identifier>EISSN: 1873-3476</identifier><identifier>DOI: 10.1016/j.ijpharm.2023.122849</identifier><identifier>PMID: 36933582</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Animals ; Antineoplastic Agents ; BLZ945 ; Carcinoma, Hepatocellular - drug therapy ; Combretastatin A4 ; Formula optimize ; Glutamic Acid ; Mice ; Mice, Inbred BALB C ; Nanoparticle ; Nanoparticles ; Polyethylene Glycols - pharmacokinetics ; Tissue Distribution</subject><ispartof>International journal of pharmaceutics, 2023-04, Vol.636, p.122849-122849, Article 122849</ispartof><rights>2023 Elsevier B.V.</rights><rights>Copyright © 2023 Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c365t-22dac13daecd59a30ebaf1faec1f0df19d1198ab7192e541c9c816dc91c050083</citedby><cites>FETCH-LOGICAL-c365t-22dac13daecd59a30ebaf1faec1f0df19d1198ab7192e541c9c816dc91c050083</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.ijpharm.2023.122849$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36933582$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Huang, Yue</creatorcontrib><creatorcontrib>Yang, Chenguang</creatorcontrib><creatorcontrib>lv, Jianlin</creatorcontrib><creatorcontrib>Zhang, Yu</creatorcontrib><creatorcontrib>Wang, Kun</creatorcontrib><creatorcontrib>Ma, Lili</creatorcontrib><creatorcontrib>Liu, Zhilin</creatorcontrib><creatorcontrib>Yu, Haiyang</creatorcontrib><creatorcontrib>Li, Mingqiang</creatorcontrib><creatorcontrib>Tang, Zhaohui</creatorcontrib><title>Formula optimization and in vivo study of poly(L-glutamic acid)-g-methoxy poly(ethylene glycol)/combretastatin A4/BLZ945 nanoparticles for cancer therapy</title><title>International journal of pharmaceutics</title><addtitle>Int J Pharm</addtitle><description>[Display omitted]
Poly(L-glutamic acid)-g-methoxy poly(ethylene glycol)/Combretastatin A4 (CA4)/BLZ945 nanoparticles (CB-NPs) have shown great potential in synergistic cancer therapy. However, it is still unclear how the nanoparticles’ formula, such as injection dose, active agent ratio, and drug loading content, affects the side effects and in vivo efficacy of CB-NPs. In this study, a series of CB-NPs with different BLZ945/CA4 (B/C) ratios and drug loading contents were synthesized and evaluated on a hepatoma (H22) tumor-bearing mice model. The injection dose and B/C ratio were found to have a significant influence on the in vivo anticancer efficacy. The CB-NPs 20 with B/C weight ratio of 0.45/1, and total drug loading content (B + C) of 20.7 wt%, showed the highest potential for clinical application. Systematic pharmacokinetics, biodistribution, and in vivo efficacy evaluation for CB-NPs 20 have been finished, which may provide significant instruction for medicine screening and clinical application.</description><subject>Animals</subject><subject>Antineoplastic Agents</subject><subject>BLZ945</subject><subject>Carcinoma, Hepatocellular - drug therapy</subject><subject>Combretastatin A4</subject><subject>Formula optimize</subject><subject>Glutamic Acid</subject><subject>Mice</subject><subject>Mice, Inbred BALB C</subject><subject>Nanoparticle</subject><subject>Nanoparticles</subject><subject>Polyethylene Glycols - pharmacokinetics</subject><subject>Tissue Distribution</subject><issn>0378-5173</issn><issn>1873-3476</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkc-O0zAQxiMEYsvCI4B83D2k9dj55xPaXbELUiUucOFiufakdeXEwXYqwpvwtqRKlyunmdF8M59mfln2HugaKFSb49oeh4MK3ZpRxtfAWFOIF9kKmprnvKirl9mK8rrJS6j5VfYmxiOltGLAX2dXvBKclw1bZX8efehGp4gfku3sb5Ws74nqDbE9OdmTJzGNZiK-JYN3080237sxqc5qorQ1t_k-7zAd_K9p6c_55LBHsneT9u52o323C5hUTPPqntwVm_vtD1GUpFe9H1RIVjuMpPWBaNVrDCQdMKhhepu9apWL-O4Sr7Pvj5--PXzOt1-fvjzcbXPNqzLljBmlgRuF2pRCcYo71UI7l9BS04IwAKJRuxoEw7IALXQDldECNC0pbfh1drPsHYL_OWJMsrNRo3OqRz9GyWoBvOYUztJykergYwzYyiHYToVJApVnKvIoL1TkmYpcqMxzHy4W465D82_qGcMs-LgIcD70ZDHIqC3O3zA2oE7SePsfi7-agqPP</recordid><startdate>20230405</startdate><enddate>20230405</enddate><creator>Huang, Yue</creator><creator>Yang, Chenguang</creator><creator>lv, Jianlin</creator><creator>Zhang, Yu</creator><creator>Wang, Kun</creator><creator>Ma, Lili</creator><creator>Liu, Zhilin</creator><creator>Yu, Haiyang</creator><creator>Li, Mingqiang</creator><creator>Tang, Zhaohui</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20230405</creationdate><title>Formula optimization and in vivo study of poly(L-glutamic acid)-g-methoxy poly(ethylene glycol)/combretastatin A4/BLZ945 nanoparticles for cancer therapy</title><author>Huang, Yue ; Yang, Chenguang ; lv, Jianlin ; Zhang, Yu ; Wang, Kun ; Ma, Lili ; Liu, Zhilin ; Yu, Haiyang ; Li, Mingqiang ; Tang, Zhaohui</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c365t-22dac13daecd59a30ebaf1faec1f0df19d1198ab7192e541c9c816dc91c050083</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Animals</topic><topic>Antineoplastic Agents</topic><topic>BLZ945</topic><topic>Carcinoma, Hepatocellular - drug therapy</topic><topic>Combretastatin A4</topic><topic>Formula optimize</topic><topic>Glutamic Acid</topic><topic>Mice</topic><topic>Mice, Inbred BALB C</topic><topic>Nanoparticle</topic><topic>Nanoparticles</topic><topic>Polyethylene Glycols - pharmacokinetics</topic><topic>Tissue Distribution</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Huang, Yue</creatorcontrib><creatorcontrib>Yang, Chenguang</creatorcontrib><creatorcontrib>lv, Jianlin</creatorcontrib><creatorcontrib>Zhang, Yu</creatorcontrib><creatorcontrib>Wang, Kun</creatorcontrib><creatorcontrib>Ma, Lili</creatorcontrib><creatorcontrib>Liu, Zhilin</creatorcontrib><creatorcontrib>Yu, Haiyang</creatorcontrib><creatorcontrib>Li, Mingqiang</creatorcontrib><creatorcontrib>Tang, Zhaohui</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of pharmaceutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Huang, Yue</au><au>Yang, Chenguang</au><au>lv, Jianlin</au><au>Zhang, Yu</au><au>Wang, Kun</au><au>Ma, Lili</au><au>Liu, Zhilin</au><au>Yu, Haiyang</au><au>Li, Mingqiang</au><au>Tang, Zhaohui</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Formula optimization and in vivo study of poly(L-glutamic acid)-g-methoxy poly(ethylene glycol)/combretastatin A4/BLZ945 nanoparticles for cancer therapy</atitle><jtitle>International journal of pharmaceutics</jtitle><addtitle>Int J Pharm</addtitle><date>2023-04-05</date><risdate>2023</risdate><volume>636</volume><spage>122849</spage><epage>122849</epage><pages>122849-122849</pages><artnum>122849</artnum><issn>0378-5173</issn><eissn>1873-3476</eissn><abstract>[Display omitted]
Poly(L-glutamic acid)-g-methoxy poly(ethylene glycol)/Combretastatin A4 (CA4)/BLZ945 nanoparticles (CB-NPs) have shown great potential in synergistic cancer therapy. However, it is still unclear how the nanoparticles’ formula, such as injection dose, active agent ratio, and drug loading content, affects the side effects and in vivo efficacy of CB-NPs. In this study, a series of CB-NPs with different BLZ945/CA4 (B/C) ratios and drug loading contents were synthesized and evaluated on a hepatoma (H22) tumor-bearing mice model. The injection dose and B/C ratio were found to have a significant influence on the in vivo anticancer efficacy. The CB-NPs 20 with B/C weight ratio of 0.45/1, and total drug loading content (B + C) of 20.7 wt%, showed the highest potential for clinical application. Systematic pharmacokinetics, biodistribution, and in vivo efficacy evaluation for CB-NPs 20 have been finished, which may provide significant instruction for medicine screening and clinical application.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>36933582</pmid><doi>10.1016/j.ijpharm.2023.122849</doi><tpages>1</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0378-5173 |
| ispartof | International journal of pharmaceutics, 2023-04, Vol.636, p.122849-122849, Article 122849 |
| issn | 0378-5173 1873-3476 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2791373018 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete |
| subjects | Animals Antineoplastic Agents BLZ945 Carcinoma, Hepatocellular - drug therapy Combretastatin A4 Formula optimize Glutamic Acid Mice Mice, Inbred BALB C Nanoparticle Nanoparticles Polyethylene Glycols - pharmacokinetics Tissue Distribution |
| title | Formula optimization and in vivo study of poly(L-glutamic acid)-g-methoxy poly(ethylene glycol)/combretastatin A4/BLZ945 nanoparticles for cancer therapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T09%3A41%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Formula%20optimization%20and%20in%20vivo%20study%20of%20poly(L-glutamic%20acid)-g-methoxy%20poly(ethylene%20glycol)/combretastatin%20A4/BLZ945%20nanoparticles%20for%20cancer%20therapy&rft.jtitle=International%20journal%20of%20pharmaceutics&rft.au=Huang,%20Yue&rft.date=2023-04-05&rft.volume=636&rft.spage=122849&rft.epage=122849&rft.pages=122849-122849&rft.artnum=122849&rft.issn=0378-5173&rft.eissn=1873-3476&rft_id=info:doi/10.1016/j.ijpharm.2023.122849&rft_dat=%3Cproquest_cross%3E2791373018%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2791373018&rft_id=info:pmid/36933582&rft_els_id=S0378517323002697&rfr_iscdi=true |